Skip to content

Veeva partners with RedHill Bio to advance Opaganib in COVID-19

September 23, 2020

Veeva Systems (NYSE:VEEV) and Bioforum collaborates with RedHill Biopharma (NASDAQ:RDHL) on a global Phase 2/3 clinical study evaluating opaganib (Yeliva, ABC294640), an orally-administered, sphingosine kinase-2 (SK2) selective inhibitor, in patients hospitalized with severe COVID-19 pneumonia requiring supplemental oxygen.

The opaganib study is set to enroll up to 270 patients. To support the study, RedHill has adopted Veeva Vault CDMS, a modern cloud platform for electronic data capture, coding, data cleaning, and reporting.

Bioforum, a global data-focused contract research organization has been selected to implement and configure Vault CDMS for this COVID-19 study.

“Our immediate goal is to compile clinical data as early as the fourth quarter of 2020 to support potential applications for emergency use authorizations of opaganib,” said Aida Bibliowicz, vice president of clinical affairs at RedHill.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: